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Given the challenges associated with the eradi-
cation of persistent viral infections, it is impor-
tant to devise and fully understand therapeutic 
strategies that achieve systemic viral elimination 
without severe pathological consequences. 
  Remarkably, a series of seminal studies conducted 
in the lymphocytic choriomeningitis virus 
(LCMV) model system (1) have revealed that 
total body elimination of a fully established per-
sistent viral infection is attainable (2, 3). If mice 
are infected at birth or in utero with LCMV 
(referred to as carrier mice), the virus establishes 
lifelong persistence in nearly every tissue com-
partment (e.g., spleen, thymus, lymph nodes, 
liver, lung, heart, kidney, central nervous sys-
tem [CNS], etc.; reference 4). T cells become 
tolerant to LCMV in carrier mice (5), and, thus, 
attempts to eliminate the pathogen through 
vaccination have been unsuccessful (6). To 
  further complicate matters, neurons are the 
  predominant LCMV-infected cell population 
residing in the brain parenchyma (2, 7). Neu-
rons reside in an immunologically specialized 
compartment (8) and do not readily express 
MHC (9, 10). Consequently, they do not rep-
resent an optimal target for T cell interactions. 
Nevertheless, one study pioneered a therapeutic 
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Given the global impact of persistent infections on the human population, it is of the 
utmost importance to devise strategies to noncytopathically purge tissues of infectious 
agents. The central nervous system (CNS) poses a unique challenge when considering such 
strategies, as it is an immunologically specialized compartment that contains a nonreplicative 
cell population. Administration of exogenously derived pathogen-specifi  c memory T cells 
(referred to as adoptive immunotherapy) to mice burdened with a persistent lymphocytic 
choriomeningitis virus (LCMV) infection from birth results in eradication of the pathogen 
from all tissues, including the CNS. In this study, we sought mechanistic insights into 
this highly successful therapeutic approach. By monitoring the migration of traceable 
LCMV-specifi  c memory CD8+ T cells after immunotherapy, it was revealed that cytotoxic 
T lymphocytes (CTLs) distributed widely throughout the CNS compartment early after immuno-
therapy, which resulted in a dramatic elevation in the activity of CNS antigen-presenting 
cells (APCs). Immunotherapy induced microglia activation as well as the recruitment of 
macrophages and dendritic cells (DCs) into the brain parenchyma. However, DCs emerged as 
the only CNS APC population capable of inducing memory CTLs to preferentially produce 
the antiviral cytokine tumor necrosis factor-𝗂, a cytokine demonstrated to be required for 
successful immunotherapeutic clearance. DCs were also found to be an essential element of 
the immunotherapeutic process because in their absence, memory T cells failed to undergo 
secondary expansion, and viral clearance was not attained in the CNS. These experiments 
underscore the importance of DCs in the immunotherapeutic clearance of a persistent viral 
infection and suggest that strategies to elevate the activation/migration of DCs (especially 
within the CNS) may facilitate pathogen clearance.
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intervention more than four decades ago in the LCMV model 
system (referred to as immunocytotherapy)  that relied on the 
adoptive transfer of LCMV-specifi  c memory splenocytes into 
carrier mice (11). Administration of immunocytotherapy re-
sulted in the complete eradication of the virus from all periph-
eral tissues as well as the CNS (7).
Analysis of immunocytotherapy in LCMV carrier mice 
provides an ideal model system to gain mechanistic insights 
into how to relieve a delicate, nonreplicative cell population 
(neurons) of a persistent viral infection. Studies in the LCMV 
model system have shown that successful immunotherapeu-
tic clearance requires the cooperative eff  orts of as few as 
350,000 CD8+ and 7,000 CD4+ memory T cells (12) as well 
as the cytokine IFN-γ (13). In addition, a unique pattern of 
clearance was observed after immunocytotherapy: most pe-
ripheral tissues are purged within 14 d, whereas 100 d are 
required to eliminate the virus from the CNS (7). Presently, 
the precise mechanism by which CNS neurons are purged of 
a persistent viral infection without obvious signs of damage 
(7, 9) remains unclear. Based on the supposition that neurons 
provide a suboptimal target for adoptively transferred CTLs 
in carrier mice as a result of their limited or negligible ex-
pression of MHC (9, 10), we theorized that professional 
APCs such as DCs might also be involved in the modus 
operandi of immunocytotherapy by promoting optimal in-
teractions and antiviral cytokine release. Unlike most pe-
ripheral tissues, DCs cannot be found in the undisturbed 
brain parenchyma (14, 15). However, several studies have 
revealed that DCs are recruited into the brain parenchyma 
during a variety of infl  ammatory conditions (16–21). More-
over, recent studies have also demonstrated that DCs are in-
volved in the optimization of secondary T cell responses to a 
variety of peripheral pathogens (22) and can exacerbate T 
cell responses in nonlymphoid tissues (23). Therefore, we set 
out to address several pertinent, unanswered questions in this 
study pertaining to the role of DCs in adoptive immuno-
therapy. First, does adoptive immunotherapy promote DC 
recruitment and antigen presentation within the CNS pa-
renchyma? Second, what is the antiviral cytokine profi  le of 
CTLs that interact with CNS DCs during immunotherapy? 
Third, are DCs absolutely required for successful immuno-
therapeutic clearance?
RESULTS
Localization of virus in the brain of an LCMV carrier mouse
LCMV distributes evenly throughout the brains of LCMV 
carrier mice (Fig. 1 A), and higher resolution colabeling anal-
yses confi  rmed previous studies (7, 9) indicating that the es-
tablishment of a persistent LCMV infection from birth results 
Figure 1.  Localization of LCMV in the brain of a carrier mouse 
persistently infected from birth. (A) Six-μm sagittal brain sections 
from C57BL/6 LCMV carrier mice (n = 3) at >8 wk of age were stained 
with a polyclonal anti-LCMV antibody (green) and a nuclear dye (red). 
Brain reconstructions were performed to illustrate the anatomical distri-
bution of LCMV. Note the equal distribution of LCMV throughout the 
brain parenchyma. (B) High resolution analyses of LCMV-infected cells 
(green; C and D) in the brain parenchyma confi  rmed that >99% of the 
cells colocalized with neuronal staining (red; B and D). Overlapping fl  uo-
rescence appears in D.
Figure 2.  Kinetics of DbGP33–41-specifi  c T cell expansion and viral 
clearance in the blood after immunocytotherapy. C57BL/6 mice 
seeded with 104 GFP+ (or Thy1.1+) DbGP33–41-specifi  c CD8+ T cells and i.p. 
infected 1 d later with LCMV served as memory donors for immuno-
cytotherapy experiments. (A) The distribution of GFP+DbGP33–41-specifi  c 
memory CD8+ T cells (green) on a splenic reconstruction is shown for 
a donor mouse 45 d after infection. The illustration is a representative 
example (n = 3) of an entire splenic cross section. Note the even 
  distribution of GFP+ memory cells throughout the spleen. Cell nuclei 
are shown in blue for anatomical purposes. (B and C) 107 memory 
  splenocytes containing GFP+DbGP33–41-specifi  c memory CD8+ T cells 
were injected i.p. into LCMV carrier mice. The viral clearance kinetics in 
relation to the expansion of GFP+DbGP33–41-specifi  c T cells in the blood 
is shown for two representative immunocytotherapy recipients (n = 3 mice). 
Note that a rapid decline in serum viral titers (gray dots) coincides per-
fectly with the expansion of GFP+DbGP33–41-specifi  c T cells (black dots). 
DbGP33–41-specifi  c T cells are represented as the percentage of CD8+ 
T cells that are GFP+.JEM VOL. 203, August 7, 2006  1965
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primarily in neuronal infection within the brain parenchyma. 
Greater than 99% of the parenchymal LCMV-positive cells 
were found to colocalize with neuronal (NeuN) staining 
(Fig. 1, B–D). Outside of the parenchyma, LCMV was also 
found to localize to the meninges, ependyma, and choroid 
plexus, which are the very same regions infected in intrac-
erebrally inoculated adult mice that succumb to the fatal 
  choriomeningitis for which LCMV is named (24).
LCMV-specifi  c memory T cells migrate into the brain 
parenchyma early after adoptive immunotherapy
To gain unique mechanistic insights into adoptive immuno-
therapy, we developed an experimental approach to monitor 
a population of LCMV-specifi  c memory CTLs during the 
immunocytotherapeutic process in LCMV carrier mice. We 
opted to monitor LCMV-specifi  c CTLs because these cells 
are required for effi   cient clearance to occur (12). To generate 
a traceable population of memory CTLs, C57BL/6 donor 
mice were seeded with 104 GFP+ (or Thy1.1+) naive TCR-
transgenic (tg) CD8+ precursors specifi   c to amino acids 
33–41 of the LCMV glycoprotein (GP) as described previ-
ously (25). 1 d after the injection of the traceable DbGP33–41-
specifi  c T cells, the memory donor mice were infected with 
105 PFU of LCMV Armstrong, which is cleared acutely 
in 8–10 d, and, afterward, memory T cells specifi  c to the 
virus emerge (26).
The distribution of memory GFP+DbGP33–41-specifi  c 
CD8+ T cells in a whole spleen cross section of a representa-
tive donor mouse at day 45 after infection is shown in Fig. 2 A. 
At this time point, the GFP+DbGP33–41-specifi  c  memory 
CTLs localize throughout the spleen. It is important to note 
that the spleen at this time point also harbors a polyclonal 
repertoire of endogenous memory T cells (both CD8+ 
and CD4+) specifi  c to LCMV (26), which can assist in viral 
clearance. Thus, GFP+DbGP33–41-specifi  c CTLs represent a 
single traceable population of memory T cells in a diverse 
antiviral repertoire.
To perform immunocytotherapy, 107 bulk memory 
  splenocytes (which included the traceable population of 
CTLs) from donor mice >45 d after infection (Fig. 2 A) were 
adoptively transferred into adult LCMV carrier mice. After 
the administration of memory splenocytes, the traceable 
  popu  lation of GFP+DbGP33–41-specifi  c CTLs expanded rap-
idly in peripheral compartments. Elevated frequencies of 
GFP+DbGP33–41-specifi   c CTLs (representing secondary ef-
fectors) were noted in the blood as early as 7–8 d after the 
therapeutic intervention, and this always coincided with a 
complete reduction in serum viral titers (Fig. 2, B and C). No 
expansion of GFP+DbGP33–41-specifi   c CTLs was observed 
when immunotherapy was performed in naive C57BL/6 
mice (unpublished data).
To evaluate the anatomical distribution of the traceable 
LCMV-specifi  c CTL and to determine whether secondary 
eff  ectors gained access to the CNS after immunocytother-
apy, we performed three-color organ reconstructions of the 
brain and spleen (a representative peripheral compartment 
known to be heavily infected by LCMV in carrier mice; 
Fig. 3; reference 4). 8 d after the administration of immuno-
cytotherapy, the spleen was completely inundated with 
GFP+DbGP33–41-specifi  c CTLs (Fig. 3, D and F), and the 
virus in this compartment was reduced to an undetectable 
level (Fig. 3, E and F), indicating that the secondary eff  ec-
tors had successfully purged the pathogen. The clearance of 
virus from the spleen also mirrored the reduction in serum 
viral titers (Fig. 2, B and C). At this same time point, the 
virus continued to persist in the CNS (Fig. 3, B and C), 
which is consistent with the delayed immunocytotherapeu-
tic clearance previously described in this compartment (7). 
Figure 3.  Distribution of DbGP33–41-specifi  c CD8+ T cells in the 
brain and spleen of an immunocytotherapy recipient. Three-color 
coronal brain (A–C) and spleen (D–F) reconstructions were generated for 
immunocytotherapy recipients (n = 3) 8 d after the administration of 
immunocytotherapy to establish the localization of GFP+DbGP33–41-specifi  c 
CD8+ T cells during the clearance of a persistent LCMV infection (red). Cell 
nuclei are shown in blue for anatomical purposes. The GFP+DbGP33–41-specifi  c 
CD8+ T cells are widely spread throughout the brain parenchyma (A) 8 d 
after immunocytotherapy, and the distribution is analogous to that of the 
remaining persistent virus (B). A three-color overlay of the coronal brain 
section is shown in C. Note that the GFP+DbGP33–41-specifi  c CD8+ 
T cells also distribute throughout the spleen (D) of the same animal; 
  however, the virus (E) has dropped to an undetectable level at this time 
point. A three-color overlay of the spleen is shown in F.1966  ADOPTIVE IMMUNOTHERAPY INDUCES CNS DENDRITIC CELL RECRUITMENT | Lauterbach et al.
Importantly, the failure to purge virus in a timely manner 
could not be explained by an inability of CTLs to access this 
compartment. GFP+DbGP33–41-specifi   c CTLs were found 
throughout the brain parenchyma within 8 d of adoptive 
immunotherapy and were dispersed in a manner that over-
lapped with the distribution of the persisting   virus (Fig. 3, 
A and C). Furthermore, the quantity of GFP+DbGP33–41-
specifi  c CTLs in the brain at this time point correlated nega-
tively (r = −0.83) with the amount of virus (as determined 
by quantitative image analysis). These data suggested that 
CTLs exerted an immunological pressure on CNS virus in 
immunotherapy recipients.
Adoptive immunotherapy induces APC recruitment 
and antigen presentation in the brain parenchyma
Because neurons do not readily express antigen-presenting 
machinery (9, 10), we postulated that professional APCs 
might contribute to the process of CNS viral clearance by 
serving as an intermediary. According to this theory, interac-
tions between peptide–MHC-presenting APCs and memory 
T cells would facilitate the release of antiviral cytokines that 
noncytopathically cleanse adjacently infected neurons. There-
fore, we set out to address whether adoptive immunotherapy 
infl  uenced APC activity within the CNS. This was accom-
plished initially by analyzing MHC class II expression on sag-
ittal brain reconstructions at day 8 after immunocytotherapy. 
MHC class II expression is restricted primarily to cell popula-
tions with the capacity to present antigens and thus serves as 
an excellent marker for APCs (e.g., DCs, macrophages, and 
microglia). Day 8 after immunotherapy was selected because 
it represents a time point when GFP+DbGP33–41-specifi  c 
CTLs were widely distributed throughout the brain paren-
chyma (Fig. 3, A and C). In contrast to the extremely low 
levels of MHC class II expression found in the brains of naive 
C57BL/6 and LCMV carrier mice, a marked increase in ex-
pression (14.4-fold; P < 0.001) was observed on sagittal brain 
sections from day 8 immunocytotherapy recipients (Fig. 4, A, 
C, E, and G). These data indicate that the LCMV carrier state 
itself did not infl  uence CNS MHC class II expression. Rather, 
the substantial elevation in expression resulted from the 
  adoptive immunotherapy.
To determine the infl  uence that adoptive immunother-
apy had on MHC I expression in the brain parenchyma, we 
next performed analyses analogous to that described for 
MHC II expression. A modest increase in MHC I expres-
sion (4.4-fold; P = 0.009) was observed in the brains of 
untreated LCMV carrier mice when compared with naive 
C57BL/6 mice (Fig. 4, B, D, and H). This indicates that 
the carrier state alone infl  uences MHC I expression in the 
CNS. Interestingly, the brains of day 8 immunotherapy 
  recipients showed a marked elevation in MHC I that far 
exceeded the levels observed in both naive (27.9-fold; 
P = 0.008) and LCMV carrier (6.3-fold; P = 0.008) mice 
(Fig. 4, B, D, F, and H). These data indicate that adoptive 
immunotherapy promotes MHC I as well as MHC II ex-
pression in the brain parenchyma.
To establish the identity/source of the APCs that local-
ized within the brains of immunocytotherapy recipients and 
to determine the kinetics of APC recruitment in relation 
to the infi  ltration of Thy1.1+DbGP33–41-specifi  c CTLs, we 
performed seven-color digital fl  ow cytometric analyses at 
various time points after immunocytotherapy. This meth-
odology permitted the simultaneous analysis of microglia, 
macrophages, DCs, and DbGP33–41-specifi  c CTLs in a single 
CNS sample obtained from individual immunocytotherapy 
recipients at the indicated time points (days 1, 3, 5, and 7). 
Seven-color analyses were used to ensure that the three 
APC populations (which are all potential sources of MHC 
class II) could be distinguished from one another and 
from CNS-  infi  ltrating mononuclear cell populations that 
share common markers. For example, CD11c (a prototypic 
Figure 4.  Elevated MHC class I and II expression in the brains of 
immunocytotherapy recipients. Representative sagittal brain sections 
from naive (A and B; n = 4), LCMV carrier (C and D; n = 4), and LCMV 
carrier 8 d after immunocytotherapy (E and F; n = 4) were stained with 
an antibody directed against MHC class II (A, C, and E) or MHC class I 
(B, D, and F; green). Note the marked increase in the level of MHC class II 
(E; 14.4-fold increase) and class I (F; 27.9-fold increase) expression on 
sagittal brain reconstructions obtained from immunocytotherapy recipi-
ents. A modest increase in MHC I expression was also observed in LCMV 
carrier mice that did not receive immunotherapy (D; 4.4-fold). Cell nuclei 
are shown in blue. An image analysis program was used to quantify the 
amount of MHC class II (G) and I (H) staining on the sagittal brain sections 
shown in A–F. The data are represented as the mean + SD (error bars). 
Statistical differences from naive mice as determined by a one-way 
ANOVA (P < 0.05) are denoted by asterisks.JEM VOL. 203, August 7, 2006  1967
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DC marker) is known to be expressed on activated T cells 
and NK cells (27, 28). CD11b (a macrophage/microglia/
conventional DC marker) can also be expressed on activated 
T cells (28). To minimize errors resulting from marker 
overlap, we included a “dump channel” in our fl  ow cyto-
metric studies to exclude T cells (CD3), NK cells (NK1.1), 
and B cells (CD19) from our analyses of microglia, macro-
phages, and DCs. We also used the common leukocyte 
marker CD45 to distinguish resident microglia from tran-
sient blood-derived APCs such as macrophages and DCs. 
It was reported previously that CNS microglia express low 
to intermediate levels of CD45 and could always be distin-
guished from blood-derived APCs, which express high 
  levels of CD45 (29, 30).
Figure 5.  Kinetics of APC recruitment into the CNS after immuno-
cytotherapy. (A) The recruitment kinetics of Thy1.1+DbGP33–41-specifi  c 
CD8+ T cells (top), macrophages (middle), and DCs (bottom) into the CNS 
was evaluated in immunocytotherapy recipients (n = 3) at the indicated 
time points. The plots refl  ect a single animal and represent the mean of 
the group. The top panels are gated on CD45+CD8+ T cells, and the per-
centages denote the frequency of Thy1.1+DbGP33–41-specifi  c CD8+ T cells. 
Note the substantial increase of antigen-specific T cells over time. 
The gates and corresponding percentages in the middle panels illustrate 
macrophages (CD45hiCD11b+) negatively gated on CD3 (to exclude T cells), 
CD19 (to exclude B cells), NK1.1 (to exclude NK cells), and CD11c (to ex-
clude DCs). Note that the presence of macrophages in the CNS increases 
substantially over time. The bottom panels illustrate the percentages of 
activated microglia (CD45low/intCD11c+; left) and DCs (CD45hiCD11c+; right) 
negatively gated on CD3 and NK1.1. Note the increase in the frequency of 
DCs in the CNS over time and the fact that CD45int microglia also up-
regulate CD11c at day 7 after immunocytotherapy. (B and C) The math-
ematical relationship between the frequency of Thy1.1+DbGP33–41-specifi  c 
CD8+ T cells and macrophages over time (i.e., days 1, 3, 5, and 7) is shown 
in B. The relationship between Thy1.1+DbGP33–41-specifi  c CD8+ T cells 
and DCs is shown in C. Note the near perfect direct linear relationship 
between the variables in both cases. Correlation coeffi  cients (r) and P 
values were calculated using a Pearson Product Moment correlation test 
(P < 0.05). (D and E) The absolute number of macrophages (D) and DCs 
(E) were calculated for naive C57BL/6, LCMV carrier, and day 8 immuno-
cytotherapy mice using the fl  ow cytometric parameters described in A. 
Data are represented as the mean + SD (error bars). Asterisks denote 
statistical signifi  cance as determined by a one-way ANOVA (P < 0.05). 
The fold increase in the number of macrophages and DCs is also indicated 
on the graphs.1968  ADOPTIVE IMMUNOTHERAPY INDUCES CNS DENDRITIC CELL RECRUITMENT | Lauterbach et al.
Using the aforementioned methodology, we simultane-
ously monitored DCs (CD45hiCD3−NK1.1−CD19−CD11c+), 
macrophages (CD45hiCD3−NK1.1−CD19−CD11c−CD11b+), 
microglia (CD45low/intCD3−NK1.1−CD19−CD11b+), and 
DbGP33–41-specifi  c CTLs (CD45hiCD8+Thy1.1+) within the 
CNS of immunocytotherapy recipients over time.   Because 
the naive brain parenchyma is normally devoid of DCs 
(14, 15), we were particularly interested in whether adop-
tive immunotherapy induced the recruitment of this potent 
APC into the CNS. Thy1.1+DbGP33–41-specifi  c CTLs were 
observed in the CNS within 1 d of adoptive immunother-
apy, and this early entry did not appreciably impact the CNS 
APC populations (Fig. 5 A). Nonactivated (CD45low) micro-
glia represented the primary CNS APC population at this 
time, and the levels of macrophages and DCs were similar 
to those observed in LCMV carrier mice that did not re-
ceive immunocytotherapy (unpublished data). Over time, 
the frequency of Thy1.1+DbGP33–41-specifi  c CTLs increased 
from 2.8% (day 1) to 38.3% (day 7), and this coincided with 
marked changes in the three APC populations. Thy1.1+
I-AbGP61–80-specifi  c CD4+ helper T cells also traffi   cked into 
the CNS by day 7 after immunotherapy, although their fre-
quency and numbers were reduced when compared with the 
traceable CTLs (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20060039/DC1).
Microglia shifted from CD45low to CD45int between days 
1 and 5 (not depicted) and up-regulated CD11c by day 7, 
  indicating that these cells became activated as a consequence of 
the adoptive immunotherapy (Fig. 5 A, bottom). CD11c ex-
pression on activated microglia was reported previously (19, 31); 
nevertheless, microglia (CD45low/int) can be easily distinguished 
from DCs (CD45hi) based on the expression of CD45 (Fig. 
5 A, bottom). Macrophages (CD45hiCD11c−CD11b+) and 
DCs (CD45hiCD11c+) increased signifi  cantly in the CNS of 
immunotherapy recipients over time, and this increase corre-
lated almost perfectly (r = 1.000 for macrophages, and r = 0.997 
for DCs) with the infi   ltration of Thy1.1+DbGP33–41-specifi  c 
CTLs (Fig. 5, B and C). By day 7, 48,113 + 10,317 macro-
phages (94-fold increase; P = 0.029) and 4,063 + 1,588 DCs 
(10-fold increase; P = 0.004) could be extracted from the CNS 
of immunocytotherapy recipients. These two populations are 
normally represented at extremely low numbers in the CNS of 
naive C57BL/6 and LCMV carrier mice (Fig. 5, D and E).
Only CNS DCs stimulate memory CTLs
Because each of the aforementioned CNS APC populations 
has the potential to stimulate adoptively transferred memory 
T cells in situ, it is important to establish which populations 
(if any) are operational during the early phase of persistent 
  viral clearance. To address this issue, we fl  ow cytometrically 
sorted DCs, macrophages, and microglia from the CNS of day 
8 immunocytotherapy recipients and cultured them ex vivo 
with purifi  ed  Thy1.1+DbGP33–41-specifi   c memory CD8+ 
T cells for 24 h. After the culture period, we evaluated whether 
the memory CTLs had produced two antiviral cytokines 
(IFN-γ and TNF-α) known to be rapidly expressed after 
  reexposure to cognate antigen (32). Thus, this ex vivo assay 
enabled us to identify which CNS-derived APCs were pre-
senting LCMV peptides in immunocytotherapy recipients.
As a positive control, memory CTLs were incubated with 
splenic DCs and macrophages obtained from LCMV carrier 
Figure 6.  Stimulatory capacity of APCs extracted from the CNS of 
immunocytotherapy recipients. DCs (CD45hiCD3−NK1.1−CD19−CD11c+) 
and macrophages (CD45hiCD3−NK1.1−CD19−CD11c−CD11b+) were fl  ow 
cytometrically sorted from the spleen and CNS of C57BL/6 naive, LCMV 
carrier, and day 8 immunocytotherapy recipients (see Materials and meth-
ods for details). Microglia (CD45low/intCD3−NK1.1−CD19−CD11b+) were only 
sorted from the CNS of day 8 immunocytotherapy recipients. The sources 
of the APCs are indicated on the left. Thy1.1+DbGP33–41-specifi  c memory 
CD8+ T cells were incubated with the denoted APCs (using a 1:2 T cell/DC 
ratio) for a 24-h period and stained intracellularly with antibodies directed 
against IFN-γ (y axis) and TNF-α (x axis). Each FACs plot is gated on 
Thy1.1+CD8+ cells and denotes the frequency of IFN-γ+ (top left quadrant), 
IFN-γ+ TNF-α+ (top right quadrant), and TNF-α+ (bottom right quadrant) 
cells. No cytokine production was observed when CTLs were left unstimu-
lated or combined with APCs from naive mice. APCs extracted from the 
spleens of LCMV carrier mice were used as a positive control. Note that 
DCs (but not macrophages) obtained from carrier spleens induced a 
marked number of IFN-γ+– and IFN-γ+ TNF-α+–producing CTLs, whereas 
DCs obtained from the spleens and CNS of immunotherapy recipients in-
duced mainly TNF-α+ producers. Macrophages and microglia from immuno-
therapy recipients were unable to stimulate memory CTLs. These data are 
representative of three to fi  ve experiments.JEM VOL. 203, August 7, 2006  1969
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mice. Both APC populations are known to harbor LCMV 
antigen in carrier mice (33); however, only DCs possessed 
the capacity to induce antiviral cytokine production in mem-
ory CTLs (Fig. 6, middle row). When APCs were extracted 
from immunotherapy recipients, it was revealed that of the 
three CNS APC populations, only DCs (not macrophages or 
microglia) were capable of inducing cytokine production by 
memory CTLs (Fig. 6, bottom row). Moreover, the cytokine 
profi  le in the restimulated memory CTLs was heavily biased 
toward TNF-α production. A similar pattern emerged when 
APCs from immunotherapy spleens were analyzed (Fig. 6, 
fourth row). The bias toward TNF-α production is quite in-
teresting given that the memory CTLs clearly have the ca-
pacity to simultaneously synthesize both IFN-γ and TNF-α 
(Fig. 6, middle row; reference 32).
Because CNS-infi  ltrating DCs were the only APC popu-
lation capable of restimulating memory CTLs ex vivo, we 
next examined whether these cells diff  ered from the non-
stimulatory APC subsets (i.e., macrophage and microglia) in 
the expression of antigen-presenting machinery (Fig. 7, A 
and B) and costimulatory molecules (Fig. 7, C and D). To 
accomplish this objective, we examined the expression of 
MHC I (Fig. 7 A), MHC II (Fig. 7 B), B7.1 (Fig. 7 C), and 
B7.2 (Fig. 7 D) on the CNS APC subsets at day 8 after im-
munotherapy. DCs and macrophages did not diff  er from one 
another in MHC I (Db) or II expression but showed signifi  -
cantly (P < 0.05) higher levels than observed on microglia. 
Interestingly, the costimulatory molecules B7.1 and B7.2 
were signifi  cantly (P < 0.05) increased only on DCs when 
compared with macrophages and microglia in the CNS. 
These data, combined with the results from the ex vivo cul-
tures, strongly suggest that DCs are potent stimulators of 
memory CTLs in the brain parenchyma during the immuno-
therapeutic clearance of a persistent viral infection.
MHC II–expressing APCs interact with memory CTLs 
in the CNS of immunocytotherapy recipients
A marked increase in MHC II–bearing APCs was observed 
in the CNS after immunotherapy (Figs. 4 and 7), of which 
only DCs were found to stimulate DbGP33–41-specifi  c mem-
ory CTLs ex vivo. To determine whether direct interactions 
between MHC II+ APCs and DbGP33–41-specifi  c memory 
CTLs occurred within the brains of immunotherapy recipi-
ents, we conducted in situ analyses of immunological synapse 
formation (25). We demonstrated previously that in vivo 
  immunological synapse formation between CTLs and their 
  targets was associated with LFA-1 (an adhesion molecule) 
polarization toward the interface (25). Therefore, we set out to 
determine whether LFA-1 polarization could be observed be-
tween GFP+DbGP33–41-specifi  c memory CTLs and MHC II+ 
APCs in the brains of LCMV carrier mice at day 8 after 
  immunotherapy. Interestingly, we found examples of such 
interactions in the meninges, choroid plexus, and brain pa-
renchyma of immunotherapy recipients (Fig. 8). Because 
DCs were the only MHC II–bearing APC found to stimulate 
cytokine production in DbGP33–41-specifi   c CTLs ex vivo, 
these data suggest that DC–CTL interactions occur within 
the brains of immunotherapy recipients.
DCs and TNF-𝗂 are required for successful viral clearance 
after immunocytotherapy
We next addressed whether DCs were required for successful 
viral clearance in LCMV carrier mice. To accomplish this 
aim, we used a well-established tg strain of mice that ex-
presses the diphtheria toxin (DT) receptor (DTR) under the 
CD11c promoter (34). Administration of a single injection of 
DT to CD11c-DTR mice results in DC depletion within 
10–15 h that lasts for  1 wk (34). To evaluate the impor-
tance of DCs in the restimulation of adoptively transferred 
memory T cells, we established a colony of CD11c-DTR tg 
mice persistently infected with LCMV. The persistently in-
fected colony, which consisted of CD11c-DTR mice and 
wild-type littermate controls, was fi  rst injected with 2 ng/g 
DT to initiate DC depletion, and, 10 h later, the mice re-
ceived immunotherapy. The success of the immunotherapy 
in CD11c-DTR and control mice was evaluated by measur-
ing traceable Thy1.1+DbGP33–41-specifi   c CTLs (Fig. 9 A) 
and viral titers (Fig. 9 B) in the blood over time. The advan-
tage of using this approach is that individual mice can be 
Figure 7.  MHC and costimulatory molecule expression on CNS 
APCs. The expression of MHC class I (A), MHC class II (B), B7.1 (C), and 
B7.2 (D) was analyzed fl  ow cytometrically on DCs, macrophages, and mi-
croglia of day 8 immunocytotherapy recipients (n = 5). Note the elevated 
expression of B7.1 and B7.2 on CNS-infi  ltrating DCs. Data are represented 
as the mean + SD (error bars) geometric mean fluorescent intensity 
(GMFI). Asterisks denote statistical signifi  cance as determined by a one-
way ANOVA (P < 0.05). MHC I, MHC II, and B7.2 were detected with anti-
bodies conjugated to PE, and B7.1 was detected with an antibody 
conjugated to FITC. The geometric mean fl  uorescent intensities for a PE-
isotype control antibody were 4.4 + 0.8, 4.3 + 0.7, and 4.5 + 0.1 on DCs, 
macrophages, and microglia, respectively. The geometric mean fl  uorescent 
intensities for a FITC-isotype control antibody were 3.5 + 0.4, 3.3 + 0.3, 
and 13.1 + 1.0 on DCs, macrophages, and microglia, respectively. The 
geometric mean fl  uorescent intensities for all molecules analyzed on the 
three APC populations were statistically higher (P < 0.05) than the 
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monitored serially. After the administration of DT and immuno-
therapy in wild-type carrier mice, a robust expansion of 
Thy1.1+DbGP33–41-specifi  c CTLs was observed in the blood 
within 8 d (Fig. 9 A), which coincided with a reduction in 
  serum viral titers (Fig. 9 B). In stark contrast, CD11c-DTR 
mice receiving the same regimen showed minimal expansion of 
Thy1.1+DbGP33–41-specifi  c CTLs (Fig. 9 A) and no reduction 
in serum viral titers by day 18 after immunotherapy (Fig. 9 B).
To determine whether DC depletion also interfered with 
the CTL and APC recruitment into the CNS, we quantifi  ed 
the number of Thy1.1+DbGP33–41-specifi  c CTLs (Fig. 9 C) 
and APCs (Fig. 9 D) in the CNS of tg and littermate controls 
at day 8 after immunotherapy, a time point when DCs were 
shown to return to baseline levels in the CD11c-DTR system 
(34). At day 8 after immunotherapy, a 24-fold decrease in the 
number of Thy1.1+DbGP33–41-specifi  c CTLs was observed in 
the CD11c-DTR carrier mice. Furthermore, the CD11c-
DTR mice did not show the characteristic APC changes as-
sociated with immunotherapy (Figs. 4 and 5). Specifi  cally, 
a reduced number of DCs (Fig. 9 D), macrophages (not de-
picted), and activated microglia (not depicted) was observed 
in the CNS of CD11c-DTR mice at day 8. Finally, to deter-
mine the long-term impact of DC depletion on the immuno-
therapeutic process, we measured CNS viral titers at day 125 
after immunotherapy, a time point past the 100-d time win-
dow required for CNS viral clearance in carrier mice (7). At 
this time, serum viral titers were reduced to undetectable 
  levels in both CD11c-DTR and control mice (unpublished 
data). This can be explained by the fact that DCs eventually 
reemerge in CD11c-DTR mice within 1 wk after a single 
injection of DT (34). However, this single injection of DT 
before immunotherapy had a long-term impact on CNS viral 
clearance (Fig. 9 E). At 125 d after immunotherapy, four out of 
fi  ve wild-type carrier mice had no detectable virus in the CNS. 
In contrast, none of the CD11c-DTR mice had cleared the 
virus by this time point. Collectively, these data indicate that 
DCs are not only capable of restimulating memory CTLs ex 
vivo (Fig. 7) but are also required for the success of immuno-
cytotherapy in vivo.
Our ex vivo restimulation cultures also demonstrated that 
DCs extracted from immunotherapy recipients preferentially 
induced the production of TNF-α (rather than IFN-γ) by 
memory CTLs. Therefore, we set out to evaluate the impor-
tance of this antiviral cytokine by establishing a colony of 
LCMV carrier mice as well as memory donors defi  cient in 
TNF-α. Generation of TNF-α–defi  cient memory donors was 
possible because LCMV can be cleared in the absence of 
TNF-α (35). This experimental paradigm enabled us to identify 
the source of TNF-α (endogenous vs. adoptively transferred 
immune cells) if the cytokine was deemed important in viral 
clearance. When wild-type memory cells were administered 
to TNF-α–defi  cient carrier mice, viral clearance was observed 
within 2 wk. However, when TNF-α–defi  cient memory cells 
were injected into mice from the same carrier colony, no re-
ductions in serum viral titers were observed. These data dem-
onstrate that TNF-α is required for successful immunotherapy 
and must be produced by adoptively transferred rather than 
endogenous immune cells for clearance to occur.
DISCUSSION
In this study, we sought unique mechanistic insights into 
  immunocytotherapy in an attempt to better understand this 
  remarkable process. Our studies led to several important ob-
servations that link professional APCs to the successful thera-
peutic clearance of a persistent viral infection. First, we 
demonstrated that LCMV-specifi  c CTLs arrive in the CNS 
early after adoptive immunotherapy, and this correlates 
  almost perfectly with the activation/recruitment of CNS 
Figure 8.  Interactions between Thy1.1+DbGP33–41-specifi  c T cells 
and MHC II+ APCs in the CNS of immunotherapy recipients. Three-
color confocal microscopy was used to demonstrate immunological syn-
apse formation between GFP+DbGP33–41-specifi  c T cells (blue) and MHC II+ 
APCs (red) in the meninges, choroid plexus, and brain parenchyma of 
immunotherapy recipients. Immunological synapses were indicated by the 
polarization of the adhesion molecule LFA-1 (green) between the CTL and 
APC (25). Asterisks denote the engaged APC, and arrows denote the con-
tact point between the two cells. LFA-1 is expressed on both CTLs and 
APCs, but note that all of the CTL-associated LFA-1 is focused toward a 
contact point at the CTL–APC interface. Two representative examples are 
shown for day 8 immunotherapy recipients (n = 3).JEM VOL. 203, August 7, 2006  1971
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APCs (i.e., DCs, macrophages, and microglia) in the brain 
parenchyma. Second, of the three CNS APC populations, 
only DCs possessed the ability to restimulate memory CTLs 
directly ex vivo. Third, DCs extracted from immunotherapy 
recipients preferentially stimulated memory CTLs to produce 
the antiviral cytokine TNF-α, a cytokine shown in this study 
to be required in donor memory cells for successful immuno-
therapy. Finally, we demonstrated an absolute dependence of 
adoptively transferred memory T cells on DCs. In the ab-
sence of DCs, secondary eff  ector T cells failed to signifi  cantly 
expand in carrier mice after adoptive immunotherapy, CTL/
APC migration into the CNS was impaired, and CNS viral 
clearance was not attained.
It was previously surmised that the clearance of virus from 
neurons after adoptive immunotherapy did not depend on 
the activities of memory T cells within the CNS (7, 36). This 
theory was based, in part, on the failure to detect cellular in-
fi  ltrates in the brain parenchyma of immunotherapy recipi-
ents (7). By using more sensitive approaches, we demonstrated 
in this study that a requisite population of traceable LCMV-
specifi  c memory CTLs can indeed be found in the CNS as 
early as 1 d after immunotherapy, and, at the peak of expan-
sion (day 8), these CTLs were spatially distributed through-
out the brain parenchyma. Neuronal viral clearance was not 
achieved at this time; however, the quantity of CTLs on sag-
ittal brain reconstructions was found to correlate negatively 
with the viral load in the CNS,  suggesting that the CTLs 
were already exerting an immunological pressure at day 8. 
These data indicate that the failure to purge CNS virus in a 
timely manner cannot be explained by an inability of CTLs 
to migrate into the brain parenchyma. Rather, it is more 
likely that the delay in clearance is related to the constraints 
imposed on CTLs by the immunologically specialized CNS.
Although LCMV-specifi  c CTLs were not able to achieve 
neuronal viral clearance with kinetics mirroring that observed 
in the periphery, their arrival in the CNS coincided perfectly 
with a dramatic elevation in MHC I and II expression. MHC 
expression was barely detectable in untreated carrier mice; 
however, by day 8 after immunotherapy, MHC I– and MHC 
II–bearing cells were distributed evenly throughout the pa-
renchyma as well as the lining of the brain. CNS microglia 
and macrophages are APCs known to express MHC II (espe-
cially upon activation), and fl  ow cytometric studies revealed 
that both cell populations were sources of MHC II in immuno-
therapy recipients. Although microglia/macrophages have 
the potential to reactivate memory T cells, we became in-
trigued by the possibility of DC involvement in the immuno-
therapeutic process given that this APC population is a potent 
stimulator of both naive (37) and memory (22) T cells. DCs 
are not normally found in the brain parenchyma (14, 15), but 
studies indicate that Toxoplasma gondii infection (16), experi-
mental autoimmune encephalomyelitis (15, 20, 21), and 
acute brain injury (19) all promote the appearance of 
  parenchymal DCs. In fact, one study demonstrated that DCs 
were capable of activating naive myelin-specifi  c  CD4+ 
T cells directly within the CNS (20). CNS DCs also appear 
capable of reactivating primed myelin-reactive CD4+ T cells 
during adoptive experimental autoimmune encephalomyelitis 
(21). Collectively, these data indicate that CNS DCs can 
  inadvertently promote autoimmune pathogenesis.
Figure 9.  Role of DCs and TNF-𝗂 in adoptive immunotherapy. 
(A and B) CD11c-DTR tg mice (closed circles; n = 5) and wild-type litter-
mate controls (open circles; n = 6) persistently infected with LCMV re-
ceived an i.p. injection of 2 ng/g DT followed 10 h later by an injection of 
107 memory cells that included traceable Thy1.1+DbGP33–41-specifi  c CD8+ 
T cells. Expansion of Thy1.1+DbGP33–41-specifi  c T cells (A) and viral titers 
(B) were monitored serially in the blood of mice over time. Note that 
Thy1.1+DbGP33–41-specifi  c T cells failed to expand, and serum viral titers 
remained elevated only in CD11c-DTR tg mice. The data in A are repre-
sented as the mean + SD (error bars) of the percentage of CD8+ T cells 
that are Thy1.1+. (C and D) When examined at day 8 after immunother-
apy, a substantial reduction in the number of Thy1.1+DbGP33–41-specifi  c 
T cells (C; 23.8-fold decrease) and DCs (D; 7.1-fold decrease) was observed 
in the CNS of CD11c-DTR tg mice. (E) CNS viral clearance was also im-
paired at day 125 after immunotherapy in CD11c-DTR tg mice. The mean 
viral titer (PFU/gram) for each group is indicated on the bar graph. Aster-
isks denote statistical signifi  cance as determined by a Student’s t test 
(P < 0.05). (F) B6 × 129 LCMV carrier mice defi  cient in TNF-α received 
2 × 107 wild-type (closed circles) or TNF-α KO (closed triangles) memory 
splenocytes. Carrier mice receiving no cells (open circles) served as a neg-
ative control group. Serum viral titers (represented as PFU/milliliter on the 
y axis) were evaluated at the time points denoted on the x axis. Note the 
failure of TNF-α–KO memory splenocytes to reduce serum viral titers. 
The data illustrated on all graphs represent the mean of three to seven 
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Although CNS DCs can facilitate undesirable patho-
genesis (20, 21), we demonstrate that a diametrically opposed 
outcome does exist upon DC migration into the CNS. 
As a consequence of immunotherapy, a substantial number 
of DCs were recruited into the brain parenchyma. These DCs 
showed an elevated expression of costimulatory molecules 
(B7.1/B7.2) as well as antigen-presenting machinery (MHC 
I/II) and were the only APC population capable of restimulat-
ing memory CTLs ex vivo. The selective stimulatory capacity 
of DCs could not be explained by a failure of other APC pop-
ulations to become activated or migrate into the CNS. Mac-
rophages were observed in the CNS after immunotherapy, yet 
these cells failed to restimulate memory CTLs. Microglia were 
also unable to restimulate memory CTLs despite up-regulating 
CD11c, a marker thought to signify microglial transformation 
into a DC-like cell population (31). Thus, DCs alone can 
  harbor the potential to stimulate memory T cells in the CNS 
without initiating a pathogenic cascade.
Given that stimulatory DCs are recruited into the brain 
parenchyma as a consequence of immunotherapy, we propose 
that this professional APC population may participate in the 
noncytopathic clearance of neurons by sustaining the activ-
ities of the antiviral CTL or by promoting antiviral cytokine 
release within the brain parenchyma. T cells have the capacity 
to purge viruses noncytopathically through cytokine release 
(38), and engagement of peptide–MHC-bearing DCs in the 
brain parenchyma may favor viral clearance from adjacent 
neurons through this mechanism. In support of this theory, 
we demonstrated that CTLs engaged MHC II–bearing APCs 
in the CNS of immunotherapy recipients. We further dem-
onstrated that DCs were the only MHC II+ APC extracted 
from the CNS of immunotherapy recipients that induced 
memory CTLs to produce TNF-α and, to a limited degree, 
IFN-γ. Although DCs from immunotherapy recipients pref-
erentially induced TNF-α production through an as yet un-
known mechanism, both TNF-α and IFN-γ (13) are required 
to achieve total body clearance in LCMV carrier mice.
One of the most important observations from this study 
was the dependence of memory T cells on DCs for successful 
immunotherapeutic clearance. In DC-depleted carrier mice, 
adoptively transferred memory CTLs demonstrated a dra-
matic reduction in secondary expansion and were impaired 
in their ability to purge LCMV systemically as well as from 
the CNS. DC depletion also signifi  cantly reduced CTL and 
APC migration/activation in the CNS of immunotherapy 
recipients. It is possible that memory CTLs also depend on 
macrophages for restimulation, as a recent study demon-
strated that certain macrophage populations are depleted in 
CD11c-DTR tg mice (39). However, we consider this pos-
sibility unlikely given that macrophages derived from the 
CNS or spleen of immunotherapy recipients did not stimu-
late memory CTLs ex vivo. DCs likely represent the main 
APC population required for the optimization of secondary 
T cell responses to pathogens (22), and we postulate that this 
reliance on DCs becomes even greater when memory T cells 
are transferred into a host heavily burdened with a systemic 
viral infection. Our results demonstrate clearly that memory 
T cells require DCs for effi   cient secondary expansion in car-
rier mice; however, it remains to be determined whether 
DCs are continually required to sustain the activities of mem-
ory T cells in the CNS during the therapeutic clearance of 
a persistent viral infection. This latter scenario seems likely 
given the near perfect correlation between CTLs and stimu-
latory DC recruitment into the CNS after immunotherapy, 
and studies to evaluate this possibility are presently ongoing.
In conclusion, immunocytotherapy is a remarkably effi   -
cient means to achieve systemic clearance of a persistent viral 
infection. The precision and effi   cacy of this process is best 
exemplifi  ed by the ability of memory T cells to operate 
within the confi  nes of the immunologically specialized CNS 
and noncytopathically purge virus from a cell population 
(neurons) that does not readily express MHC (9, 10). Thus, 
clearance of a persistent viral infection from the CNS is at-
tainable. In this study, we demonstrated that adoptive immuno-
therapy infl  uenced DC activity within the CNS, and the 
success of this therapeutic intervention was dependent on this 
potent APC subset. Therefore, we propose that a therapeutic 
enhancement of DC recruitment into the CNS may provide 
an excellent strategy to promote (or accelerate) the clearance 
of a persistent viral infection.
MATERIALS AND METHODS
Mice. C57BL/6, C57BL/6 Thy1.1+DbGP33–41 TCR-tg, C57BL/6 
Thy1.1+I-AbGP61–80 TCR-tg, C57BL/6 GFP+DbGP33–41 TCR-tg, 
C57BL/6 CD11c-DTR tg, and C57BL/6 × 129 TNF-α–defi  cient mice 
were bred and maintained in a closed breeding facility at The Scripps 
  Research Institute. C57BL/6 Thy1.1+I-AbGP61–80 TCR-tg mice were a gift 
of H. Hengartner (Institute of Experimental Immunology, University 
  Hospital Zurich, Zurich, Switzerland). The handling of all mice conformed 
to the requirements of the National Institutes of Health and The Scripps 
Research Institute animal research committee.
Virus. The parental Armstrong 53b of LCMV, which is a triple-plaque 
  purifi  ed clone from Armstrong CD 1371 (40), was used for all experiments. 
1-d-old C57BL/6 and C57BL/6 × 129 TNF-α–defi  cient mice were in-
fected with 103 PFU of LCMV Armstrong to generate persistently infected 
adult mice as described previously (7). Because LCMV is known to spread 
through vertical transmission (i.e., mother to off  spring), the resultant mice 
were bred to establish a persistently infected colony (referred to as LCMV 
carrier mice). Mice obtained from this LCMV carrier colony were used for 
all lines of experimentation. To establish a carrier colony of CD11c-DTR tg 
mice, persistently infected female C57BL/6 mice were crossed with unin-
fected male CD11c-DTR mice. All mice derived from this cross were per-
sistently infected with LCMV. Viral titers were determined by plaque assay 
on Vero cells as described previously (41).
Immunocytotherapy. To generate LCMV memory donors for immuno-
cytotherapy experiments, C57BL/6 mice were seeded with 104 naive GFP+ 
(or Thy1.1+) DbGP33–41-specifi  c CD8+ T cells (25, 42). For cotransfer ex-
periments, C57BL/6 mice were seeded with 104 naive Thy1.1+ DbGP33–41-
specifi  c CD8+ T cells and 104 naive Thy1.1+ I-AbGP61–80-specifi  c CD4+ 
T cells. All naive cells were purifi  ed from TCR-tg mice by negative selec-
tion (StemCell Technologies Inc.). The enrichment procedure resulted in a 
purity of >98%. 1 d after the adoptive transfer, mice were infected i.p. with 
105 PFU of LCMV Armstrong. For the TNF-α KO experiments shown in 
Fig. 9, C57BL/6 × 129 TNF-α KO mice were infected with the same dose 
of virus to generate cytokine-defi  cient memory cells. Because TNF-α KO JEM VOL. 203, August 7, 2006  1973
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mice infected i.p. with LCMV Armstrong mounted a robust anti-LCMV 
CTL response and cleared the virus, they could be used as memory donors. 
These donor mice were not seeded with DbGP33–41-specifi  c CD8+ T cells. 
Splenocytes were harvested from all mice at time points >45 d after infec-
tion, when LCMV-specifi  c memory T lymphocytes are known to be present 
in the spleen (26, 43). For all immunocytotherapy experiments, 1–2 × 107 
memory splenocytes either unseeded (TNF-α KO experiments) or seeded 
with traceable DbGP33–41-specifi  c CD8+ T cells (see Fig. 2 A for an example) 
were injected i.p. into LCMV carrier mice.
DC depletion. To deplete DCs, CD11c-DTR tg mice persistently infected 
with LCMV were injected i.p. with 2 ng/g DT in 100 μl PBS. This dose of 
DT was selected from a titration experiment in which CD11c-DTR carrier 
mice were injected with 4, 2, and 1 ng/g of toxin. All doses of DT resulted in 
a similar level of splenic DC depletion 1 d after injection. The 2-ng/g (instead 
of the traditional 4 ng/g; reference 34) dose of DT was ultimately used for all 
experiments because no evidence of toxicity was observed with this dosage.
Mononuclear cell isolations and tissue processing. To obtain cell sus-
pensions for fl  ow cytometric analyses/stimulation cultures, the spleens and 
CNS were harvested from mice after an intracardiac perfusion with a 0.9% 
saline solution to remove the contaminating blood lymphocytes. Splenocytes 
and brain-infi  ltrating leukocytes were incubated with 1 ml collagenase D 
(1 mg/ml; Roche) at 37°C for 20 min and mechanically disrupted through 
a 70-μm fi   lter. Splenocytes were treated with RBC lysis buff  er  (0.14 
M NH4Cl and 0.017 M Tris-HCl, pH 7.2), washed twice, and analyzed. 
To extract brain-infi  ltrating leukocytes, homogenates were resuspended in 
90% Percoll (4 ml), which was overlaid with 60% Percoll (3 ml), 40% Percoll 
(4 ml), and fi  nally 1× HBSS (3 ml). The Percoll gradients were then centri-
fuged at 1,500 rpm for 15 min, after which the band corresponding to 
mononuclear cells was carefully extracted, washed, and ultimately analyzed. 
The number of mononuclear cells was determined from each organ prepara-
tion and used to calculate the absolute number of specifi  c cell populations. 
PBMCs were obtained by centrifugation after incubating (for 1 h on ice) 
a capillary of blood ( 210 μl) with 10 ml RBC lysis buff  er. To visualize 
GFP+DbGP33–41-specifi  c T cells in situ, mice received an intracardiac perfu-
sion of 4% paraformaldehyde. Brains and spleens were then removed and 
  incubated for 24 h in 4% paraformaldehyde and for an additional 24 h in 
30% sucrose. Afterward, tissues were submerged in optimal cutting temperature 
(Tissue-Tek) and frozen on dry ice. For all other immunohistochemical 
analyses, fresh, unfi  xed tissues were frozen in optimal cutting temperature.
Flow cytometry. The following antibodies purchased from BD Biosci-
ences were used to stain splenocytes and brain-infi  ltrating  lymphocytes: 
anti-B7.1-FITC, anti-B7.2-PE, CD11b-PE-CY7, anti-CD11b-PerCP-
Cy5.5, anti-CD11c-APC, anti-CD19-PE, anti-CD3-PE, anti-CD3-PerCP, 
anti-CD45.2-FITC, anti-CD45.2-biotin, anti-CD8-PE, anti-CD8-APC, 
anti-CD8-APC-CY7, anti-Db-PE, anti-I-Ab-PE, anti-IFNγ-APC, anti-
NK1.1-PE, anti-NK1.1-PerCP, anti-Thy1.1-PerCP, and anti-TNFα-PE. 
Anti-CD8–Pacifi  c blue was purchased from Caltag, and streptavidin–Pacifi  c 
blue was purchased from Invitrogen. Before staining, all cell preparations 
were blocked with 3.3 μg/ml anti–mouse CD16/CD32 (Fc block; BD 
  Biosciences) in PBS containing 1% FBS for 10 min. The Fc block was also 
included in all 20-min surface stains. Cells were acquired using a fl  ow 
  cytometer (Digital LSR II; Becton Dickinson), which allows up to 10-color 
detection by using four diff  erent excitation lasers. Flow cytometric data were 
analyzed with FlowJo software (Tree Star, Inc.).
CNS APC stimulation cultures. Mononuclear cells were extracted from 
the CNS/spleens of LCMV carrier mice 8 d after immunocytotherapy as 
described in Mononuclear cell isolations and tissue processing. To obtain a 
suffi   cient number of CNS APCs, 12 immunocytotherapy recipients were 
pooled together. APCs extracted from the spleens of LCMV carrier mice 
(not receiving immunocytotherapy) and naive C57BL/6 mice served as 
  controls. The extracted mononuclear cell preparations were then stained 
with the following antibodies: CD45.2-FITC (leukocyte marker), CD3-PE 
(T cells), CD19-PE (B cells), NK1.1-PE (NK cells), CD11b-PerCP-Cy5.5 
(myeloid marker), and CD11c-APC (DCs). Because CD11b and CD11c can 
be up-regulated on cells other than APCs (e.g., T cells and NK cells), a 
“dump channel” was included in the fl  ow cytometric sorts to ensure a highly 
enriched population of APCs that did not include contaminating leukocyte 
populations. CD3-PE, CD-19-PE, and NK1.1-PE were used to exclude 
T, B, and NK cells, respectively. Flow cytometric sorting was performed us-
ing a cell sorter (FACS Aria; BD Biosciences) to simultaneously collect DCs 
(CD45hiCD3−NK1.1−CD19−CD11c+), macrophages (CD45hiCD3−NK1.
1−CD19−CD11c−CD11b+), and microglia (CD45low/intCD3−NK1.1−CD1
9−CD11b+). It should be noted that cells expressing low and intermediate 
levels of CD45 (i.e., microglia) were only found in the CNS preparations.
To isolate LCMV-specifi  c memory CD8+ T cells for the stimulation 
cultures, C57BL/6 mice were seeded with 104 Thy1.1+DbGP33–41-specifi  c 
CD8+ T cells. 1 d later, mice were infected with 105 PFU of LCMV 
  Armstrong. Splenocytes were isolated from the mice at 45 d after infection, 
enriched using MACs (Miltenyi Biotec) anti-CD8 positive selection beads, 
and stained with anti-Thy1.1-PE. Flow cytometric sorting was then used to 
isolate Thy1.1+ (or DbGP33–41 specifi  c) T cells. After the fl  ow cytometric sort-
ing, all cells were resuspended in RPMI 1640 (Life Technologies) containing 
10% FBS, 1% penicillin/streptomycin, 1% l-glutamine, 1% Hepes, 1% non-
essential amino acids, 1% sodium pyruvate, and 50 μM β-mercaptoethanol. 
Afterward, 50,000 Thy1.1+DbGP33–41-specifi  c memory T cells were mixed 
with 100,000 of the indicated APC populations (1:2 T cell/DC ratio) in a 
96-well U-bottom plate for 24 h in a humidifi  ed 37°C incubator (5% CO2). 
5 μg/ml brefeldin A (Sigma-Aldrich) was added in the 19th hour of the 24-h 
culture period to block cytokine release and permit intracellular staining. Af-
ter the incubation period, cultured cells were stained with antibodies directed 
against Thy1.1, CD8, IFN-γ, and TNF-α, and the cytokine-producing 
Thy1.1+DbGP33–41-specifi  c CD8+ T cells were analyzed by fl  ow cytometry.
Immunohistochemistry. To visualize LCMV, DCs, and neurons, 6-μm 
frozen sections were cut, fi  xed with 2% formaldehyde, blocked with an 
  avidin/biotin-blocking kit (Vector Laboratories), and stained for 1 h at room 
temperature with guinea pig anti-LCMV (1:1,000), 2.5 μg/ml of Armenian 
hamster anti-CD11c (Serotec), or 1.25 μg/ml of mouse antineuronal nuclei 
(anti-NeuN; Chemicon International), respectively. To block endogenous 
mouse antibodies, sections stained with mouse anti-NeuN were preincu-
bated for 1 h at room temperature with 35 μg/ml of a Fab anti–mouse H 
and L chain antibody (Jackson ImmunoResearch Laboratories). After the 
primary antibody incubation, sections were washed, stained for 1 h at room 
temperature with a biotinylated secondary antibody (1:400; Jackson Immu-
noResearch Laboratories), washed, and stained for 1 h at room temperature 
with streptavidin–Rhodamine Red-X (1:400; Jackson ImmunoResearch 
Laboratories). All sections were costained for 5 min at room temperature 
with 1 μg/ml DAPI (Sigma-Aldrich) to visualize cell nuclei.
To visualize MHC class II, frozen sections were fi  xed with cold (−20°C) 
95% ethanol, blocked with an avidin/biotin-blocking kit, and stained for 1 h 
at room temperature with 1.0 μg/ml of rat anti–MHC class II (BD Biosciences). 
After the primary antibody incubation, sections were washed, stained for 1 h 
at room temperature with a biotinylated secondary antibody, washed, and 
stained for 1 h at room temperature with streptavidin–Rhodamine Red-X. 
For simultaneous analysis of GFP, MHC II, and LFA (Fig. 8), MHC II stain-
ing was combined with a primary antibody directed against 3 μg/ml LFA-1 
(BD Biosciences). The LFA-1 primary was visualized with a secondary anti-
body conjugated to Cy5. For colabeling of LCMV and NeuN (Fig. 1, B–D), 
frozen sections were stained as described in the beginning of this section ex-
cept that the anti-LCMV antibody was detected with an anti–guinea pig 
secondary antibody directly conjugated to FITC (1:750; for 1 h at room 
temperature). All working stocks of primary and secondary reagents were 
diluted in PBS containing 2% FBS.
Microscopy. Two- and three-color organ reconstructions to visualize the 
distribution of LCMV, MHC class II, and GFP+DbGP33–41-specifi  c CD8+ 
T cells on 6-μm frozen sections were obtained using an immunofl  uorescence 1974  ADOPTIVE IMMUNOTHERAPY INDUCES CNS DENDRITIC CELL RECRUITMENT | Lauterbach et al.
microscope (Axiovert S100; Carl Zeiss MicroImaging, Inc.) fi  tted with an 
automated xy stage, a color digital camera (Axiocam, Carl Zeiss MicroImaging, 
Inc.), and a 5× objective. Registered images were captured for each fi  eld on 
the tissue section, and reconstructions were performed using the MosaiX 
function in KS300 image analysis software (Carl Zeiss MicroImaging, Inc.). 
Higher resolution images of LCMV-infected neurons (Fig. 1, B–D) and 
  interactions between GFP+DbGP33–41-specifi  c CTLs and MHC II+ APCs 
(Fig. 8) were captured with a confocal microscope (MRC1024; Bio-Rad Lab-
oratories) fi  tted with a krypton/argon mixed gas laser (excitation at 488, 568, 
and 647 nm) and a 40× oil objective (Carl Zeiss MicroImaging, Inc.). All 
two-dimensional confocal images illustrate a single z section captured at a 
position approximating the midline of the cell.
Image analysis. The percentage of CNS tissue occupied by MHC I, MHC 
II, and LCMV staining was calculated from sagittal brain reconstructions 
(see Fig.4 and previous section) using a program written for the KS300 
  image analysis software.
Statistical analyses. Data handling, analysis, and graphical representations 
were performed using Microsoft Excel and SigmaPlot 8.0 (Systat). Statistical 
diff  erences were determined by Student’s t test or one-way analysis of vari-
ance (ANOVA; P < 0.05) using SigmaStat 2.0 (SigmaStat). Correlation co-
effi   cients were also calculated in SigmaStat using a Pearson Product Moment 
correlation test (P < 0.05).
Online supplemental material. Fig. S1 shows the recruitment of DbGP33–41-
specifi  c CD8+ and I-AbGP61–80-specifi  c CD4+ T cells into the CNS of 
immunotherapy recipients. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20060039/DC1.
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